Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .
A randomized controlled trial of risperidone and olanzapine for schizophrenic patients with neuroleptic-induced tardive dyskinesia.
OBJECTIVE To compare the efficacy of risperidone and olanzapine in schizophrenic patients with tardive dyskinesia on treatment with first-generation antipsychotics . METHOD We conducted a 24-week , rater-blinded , flexible-dose study . Sixty patients with DSM-IV schizophrenia ( n = 58 ) or schizoaffective disorder ( n = 2 ) met the DSM-IV research criteria for neuroleptic-induced tardive dyskinesia and were r and omly assigned to a risperidone or olanzapine group . The primary outcome was a comparison of the change in the total scores on the Abnormal Involuntary Movement Scale ( AIMS ) from baseline to study end point between the groups . The study was conducted from July 2000 to June 2004 . RESULTS The mean ± SD doses of risperidone and olanzapine from baseline to study end point were 1.9 ± 0.7 to 4.1 ± 1.4 mg/d and 8.1 ± 2.0 to 12.6 ± 5.4 mg/d , respectively . There were no statistically significant differences in demographic data , severity of tardive dyskinesia , or psychotic symptoms between risperidone and olanzapine groups at baseline assessment . Both groups showed significant improvement in mean ± SD AIMS total scores  ( risperidone : −7.4 ± 6.9 , P < .0001 ; olanzapine : −6.2 ± 8.0 , P = .0002 ) . However , there was a more statistically significant change in the slope of AIMS total scores in the risperidone group than in the olanzapine group ( P = .0001 ) . CONCLUSIONS Our findings demonstrated that olanzapine may not have better potential for tardive dyskinesia improvement than risperidone did . Double-blinded , fixed dose studies with a larger sample size on schizophrenic patients with tardive dyskinesia from different ethnic groups are needed to confirm the results of our study . TRIAL REGISTRATION clinical trials.gov Identifier
Findings related to effectiveness ( treatment discontinuation , quality of life , and neurocognitive improvements ) were generally consistent with those observed in non-Chinese population s. No new safety signals specific for Chinese population s were raised for olanzapine .
Chinese and non-Chinese population s with schizophrenia or bipolar disorder treated with olanzapine display broadly similar responses .
BACKGROUND Despite the burden of schizophrenia and bipolar disorder in the Chinese population , country-specific data to guide practitioners regarding antipsychotic therapy are lacking .